Chrysin as a Functional Biomaterial for Pharmaceutical Innovations

ABSTRACT Chrysin (5,7‐dihydroxyflavone), naturally occurs as a bioflavonoid, which is predominantly found in honey, propolis, and passion flowers. With its wide spectrum of pharmacological activities, such as antioxidant, anti‐inflammatory, anticancer, and neuroprotective effects, chrysin has been considered a potential functional biomaterial in pharmaceutical sciences. It has a potent therapeutic potential, but the low oral bioavailability, a rapid metabolism, and the poor hydrophobicity have stifled its clinical applications. Recent advancements in drug delivery systems, including the development of chrysin‐loaded nanoparticles and liposomes, have significantly enhanced its bioavailability and stability. These innovations have demonstrated improved therapeutic efficacy in preclinical models, suggesting chrysin's potential for treating various acute and chronic diseases. Chrysin has also demonstrated compatibility with various biomaterials, which supports its use in tissue engineering, implant coatings, and composite systems for wound healing. Chrysin's chemical and pharmacological profile, recent formulation development, its function in biomaterial‐based delivery systems, and the state of safety and regulatory considerations are all thoroughly covered in this paper. We emphasize future prospects for chrysin pharmaceutical innovation by critically assessing the body of existing literature and highlighting important obstacles, such as a lack of clinical data and regulatory restrictions. Chrysin is suggested as a promising candidate for next‐generation therapeutic uses in this paper, which attempts to close the gap between functional biomaterial development and natural product research.